NEW YORK (dpa-AFX Analyzer) – The US bank JPMorgan has raised the price target for GSK from 1,530 to 1,660 pence and left the rating at “Underweight”. The targets for 2024 made a conservative impression, wrote analyst James Gordon in a study available on Thursday. In the longer term, however, the challenges that the pharmaceutical company is exposed to will persist. Gordon increased his estimates slightly due to positive news from the oncology sector./tih/gl
Publication of the original study: May 1, 2024 / 11:28 p.m. / BST First distribution of the original study: May 2, 2024 / 12:15 a.m. / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at
At the time the news was published, the GSK share was trading with an increase of +0.60% and a price of EUR 19.61 on Lang & Schwarz (May 2, 2024, 7:54 a.m.).
Analyzing institute: JPMORGAN
Analyst: James Gordon
Company Analyzed: GSK
New stock classification: negative
New price target: 16.6
Price target old: 15.3
Currency: GBP
Time frame: 12m
also read
Discuss the values included